- Among COVID-19 patients with preexisting type 2 diabetes (T2D), blood glucose (BG) within 3.9-10.0 mmol/L is associated with improved outcomes.
Why this matters
- T2D is a common COVID-19 comorbidity, but evidence linking it to outcomes is limited.
- Retrospective, multicenter study of 7337 COVID-19 cases in Hubei Province, China.
- Funding: National Key R&D Program of China; National Science Foundation of China.
- During 28 days postadmission, with T2D (n=923) vs without (n=6385), increased risk for all-cause in-hospital mortality:
- HR, 1.49 (P=.005).
- HR was adjusted for age, sex, COVID-19 severity.
- In T2D group, with well-controlled glycemia (n=282; BG upper limit ≤10 mmol/L; average HbA1c, 7.3%) vs poorer control (n=528; BG upper limit >10 mmol/L; HbA1c, 8.1%), decreased risk for in-hospital death:
- HR, 0.13 (P<.001>
- HR adjusted for age, sex, and COVID-19 severity, comorbidities.
- Acute respiratory distress syndrome: 0.41 (P<.001 and>
- Acute heart injury: 0.21 (P=.003).
- HR: 0.14 (P=.008).
- All inpatients, from 1 Chinese province.
- No data on prehospital T2D status.
- Small number of participants with good control.